|
 |
Faculty |
 |
Statement of Need |
 |
Activity Goal |
 |
Learning Objectives |
 |
Financial Support |
 |
Target Audience |
 |
Credit Information |
The Challenges of Early Intervention in Alzheimer's Disease
neuroscienceCME Multimedia Snack
Premiere Date: Tuesday, November 4, 2014This activity offers CE credit for:
- Physicians (CME)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, November 4, 2015
Note: Credit Is No Longer Available
 | Charles B. Nemeroff, MD, PhD Professor and Chair Department of Psychiatry Mulva Clinic for the Neurosciences Director, Institute of Early Life Adversity Research Dell Medical School The University of Texas at Austin Austin, TX |
 | Anand Kumar, MD Lizzie Gilman Professor and Head Department of Psychiatry University of Illinois at Chicago College of Medicine Chicago, IL |
The rate of Alzheimer's disease and other dementias continue to grow as the U.S. population ages, and the number of individuals 65 and older continues to increase. The pathophysiological process of AD begins many years before clinically obvious symptoms appear. In addition, the concept of a presymptomatic or preclinical stage of AD is gaining acceptance in the medical community. Discussion of risk factors and careful assessments of individuals 60 or older can improve recognition and help direct treatment approaches.
Where is the field of dementia care going? This was the most asked question in last year’s sessions on Alzheimer’s disease at the 2013 Chair Summit. This neuroscienceCME Snack addresses many participants’ questions: “What new treatment targets are being investigated, what treatments seem promising, and what can we do to provide hope for patients and family?” Faculty will describe a thorough Alzheimer’s workup and discuss early diagnosis, risk factors, and the use of biomarkers and imaging to evaluate individuals for neurocognitive disorders.
This educational activity centers on the CME Outfitters Make One Change statement. This statement is crafted from pertinent quality measures or clinical guidelines as a performance challenge to all participants. The Make One Change statement for this activity is:
Annually evaluate all patients 60 and older for neurocognitive disorders.
At the end of this CE activity, participants should be able to:
- Implement routine cognitive screening to facilitate early identification and early intervention of Alzheimer's disease in patients who are over the age of 60 years.
- Discuss modifiable risk factors and quality of life with patients and family/caregivers to support and encourage their participation in their treatment process.
- Incorporate into routine practice the new diagnostic language and, when appropriate, biomarkers, PET imaging technologies, and the latest treatment approaches to optimize clinical management of patients with Alzheimer's disease.
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
Physicians and other health care professionals who treat geriatric patients.
CME Credit (Physicians):
Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST926 (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Nemeroff has disclosed that he receives grants/research support from the National Institutes of Health (NIH). He serves as a consultant to Allergen, Inc.; Eli Lilly and Company; Lundbeck; Mitsubishi Tanabe Pharma Development America; Prismic Pharmaceuticals; SK Pharma; Roche; Shire Pharmaceuticals; Taisho Pharmaceutical Inc.; Takeda Pharmaceuticals North America, Inc.; and Xhale, Inc. He serves on the scientific advisory boards of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); CeNeRx BioPharma; National Alliance for Research on Schizophrenia and Depression (NARSAD); PharmaNeuroBoost; Xhale, Inc.; and Skyland Trail. He serves on the board of directors of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); GratitudeAmerica, Inc.; NovaDel Pharma, Inc. (2011); and Skyland Trail. He is a stockholder of AbbVie Inc,; Celgene Corporation; CeNeRx BioPharma; PharmaNeuroBoost; Reevax Pharmaceuticals LLC; Seattle Genetics, Inc.; and Xhale, Inc. His other financial income sources or equity of $10,000 or more include American Psychiatric Publishing; BioPharma; CeNeRx NovaDel Pharma, Inc.; Pharmaneuroboost; Revaax Pharmaceuticals LLC; and Xhale, Inc. He holds patents for the following: method and devices for transdermal delivery of lithium (US 6,375,990B1); method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2).
Dr. Kumar has disclosed that he has received grant support from the National Institutes of Mental Health. He has received other financial or material support as the Associate Editor, American Journal of Geriatric Psychiatry.
Tony Graham, MD (content/peer reviewer) has no disclosures to report.
Robert Kennedy (planning committee) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Sandra Haas Binford, MAEd (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, and Lilly do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
SN-062-110414-11
